Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × INDUSTRY × Lymphangioma × Clear all

Phase

Phase 3 1 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

INDUSTRY 1 FED 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 26 Neoplasms 21 Breast Neoplasms 19 Neoplasm Metastasis 18 Prostatic Neoplasms 15 Stomach Neoplasms 14 Colorectal Neoplasms 14 Recurrence 13 Squamous Cell Carcinoma of Head and Neck 10 Pancreatic Neoplasms 10 Ovarian Neoplasms 10 Lung Neoplasms 10 Head and Neck Neoplasms 10 Carcinoma, Hepatocellular 10 Myasthenia Gravis 9 Urinary Bladder Neoplasms 8 Leukemia, Myeloid, Acute 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Melanoma 7 Multiple Myeloma 6 Lymphoma, Non-Hodgkin 6 Lymphoma, Large B-Cell, Diffuse 6 Cholangiocarcinoma 6 Small Cell Lung Carcinoma 5 Lymphoma, Follicular 5 Liver Neoplasms 5 Glioblastoma 5 Colonic Neoplasms 5 Carcinoma, Transitional Cell 5 Biliary Tract Neoplasms 5

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05948943 2026-02-13

EPIK-L1

Novartis

Phase 2/3 Recruiting

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

Data powered by HemOnc (CC BY 4.0) Colophon ⚡